179 related articles for article (PubMed ID: 22329596)
1. A 17-year experience of abobotulinumtoxina in cervical dystonia.
Vivancos-Matellano F; Ybot-Gorrin I; Diez-Tejedor E
Int J Neurosci; 2012 Jul; 122(7):354-7. PubMed ID: 22329596
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
3. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
8. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study.
Werdelin L; Dalager T; Fuglsang-Frederiksen A; Regeur L; Karlsborg M; Korbo L; Munck O; Winge K
Clin Neurophysiol; 2011 Nov; 122(11):2305-9. PubMed ID: 21636319
[TBL] [Abstract][Full Text] [Related]
9. A long-term follow-up of botulinum toxin A in cervical dystonia.
Mohammadi B; Buhr N; Bigalke H; Krampfl K; Dengler R; Kollewe K
Neurol Res; 2009 Jun; 31(5):463-6. PubMed ID: 19278576
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
11. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients.
Maia FM; Kanashiro AK; Chien HF; Gonçalves LR; Barbosa ER
Parkinsonism Relat Disord; 2010 Jan; 16(1):8-11. PubMed ID: 19589716
[TBL] [Abstract][Full Text] [Related]
12. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
13. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A and cervical dystonia: a seven-year follow-up.
Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC
Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174
[TBL] [Abstract][Full Text] [Related]
15. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Hauser RA; Truong D; Hubble J; Coleman C; Beffy JL; Chang S; Picaut P
J Neural Transm (Vienna); 2013 Feb; 120(2):299-307. PubMed ID: 22878514
[TBL] [Abstract][Full Text] [Related]
16. Somatosensory temporal discrimination tested in patients receiving botulinum toxin injection for cervical dystonia.
Scontrini A; Conte A; Fabbrini G; Colosimo C; Di Stasio F; Ferrazzano G; Berardelli A
Mov Disord; 2011 Mar; 26(4):742-6. PubMed ID: 21506155
[TBL] [Abstract][Full Text] [Related]
17. Cervical dystonia: clinical and therapeutic features in 85 patients.
Camargo CH; Teive HA; Becker N; Baran MH; Scola RH; Werneck LC
Arq Neuropsiquiatr; 2008 Mar; 66(1):15-21. PubMed ID: 18392407
[TBL] [Abstract][Full Text] [Related]
18. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
[TBL] [Abstract][Full Text] [Related]
19. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
20. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
J Neurol Sci; 2020 Sep; 416():117015. PubMed ID: 32682125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
